Jiayin Miao

Dr. Jiayin Miao


Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2020 in Risk Management and Healthcare Policy
Verified
Journal Article
Open access
PDF file
YCYiqian Chen
Yiqian Chen
JCJingzhen Chen
Jingzhen Chen
XCXingyu Chen
Xingyu Chen
RWRu Wang
Ru Wang
JZJianqi Zeng
Jianqi Zeng
JMJiayin Miao
Jiayin Miao
Background: Juvenile myoclonic epilepsy (JME) is the most common idiopathic generalized epilepsy syndrome, accounting for 10% of all epilepsy. However, there is limited information regarding the predictors of seizure outcome. The aim of this study was to determine the predictors of seizure outcome in JME patients. Methods: A population-based retrospective study of JME patients who were treated at the Department of Neurology of affiliated Zhongshan Hospital, Xiamen University from 2008 to 2013. Results: Sixty-three patients (30 women and 33 men) were enrolled in this study. The median age at seizure onset was 14 years old, and the average duration of epilepsy was 5 years. The onset of JME at age = 3 s were observed in 35.8% patients. Febrile seizure was noted in 28.9% of patients. Among 63 patients, 40 patients (63.5%) had remission. Multivariate analysis identified the following factors as significant predictors of seizure outcome: the onset of JME at age = 3 s runs, and febrile seizure. Conclusion: The onset of JME at age = 3 s might be associated with poor long-term seizure outcome in patients with JME.

12 August 2015 in BMC Neurology
Verified
Journal Article
Open access
PDF file
JMJiayin Miao
Jiayin Miao
FWFeng Wang
Feng Wang
WZWeihong Zheng
Weihong Zheng
XZXiaorong Zhuang
Xiaorong Zhuang
Apolipoprotein E (ApoE) gene has been reported to be associated with migraine and tension-type headache (TTH), but the results are conflicting. This study aimed to evaluate the association of ApoE with migraine by a meta-analysis. MEDLINE, ISI Web of Knowledge, The Cochrane Central Register of Controlled Trials, and EMBASE databases were searched to identify eligible studies published in English from 2000 to 2014. Data were extracted using standardized forms. The association was assessed by relative risk (RR) with 95 % confidence intervals (CIs) using a fixed or random effects model. Four studies, comprising 649 migraineurs, 229 TTH subjects and 975 controls, met all the criteria and were included in the meta-analysis. No significant difference was found comparing genotypic and allelic frequencies in the case of migraineurs versus controls and TTH subjects versus controls. Only when migraineurs and TTH subjects were considered as a whole group, ApoE4 was found to increase the relative risk of headache by 1.48 (95 % CI 1.16, 1.90; P = 0.002), compared to controls. ApoE ε4 allele is not associated with migraine susceptibility, but is positively related to headache (including migraine and TTH).

24 February 2021 in Frontiers in Oncology
Verified
Journal Article
Open access
PDF file
MZMengya Zhong
Mengya Zhong
XQXingfeng Qiu
Xingfeng Qiu
YLYu Liu
Yu Liu
YYYan Yang
Yan Yang
LGLei Gu
Lei Gu
GZGuohong Zhuang
Guohong Zhuang
Tumor necrosis factor-induced protein-8 (TIPE) is highly expressed in colorectal cancer (CRC). Decoy receptor 3 (DcR3) is a soluble secreted protein that can antagonize Fas ligand (FasL)-induced apoptosis and promote tumorigenesis. It remains unclear whether TIPE can regulate DcR3 expression. In this study, we examined this question by analyzing the relationship between these factors in CRC. Bioinformatics and tissue microarrays were used to determine the expression of TIPE and DcR3 and their correlation in CRC. The expression of TIPE and DcR3 in colon cancer cells was detected. Plasma samples were collected from CRC patients, and DcR3 secretion was measured. Then, dual-luciferase reporter gene analysis was performed to assess the interaction between TIPE and DcR3. We exogenously altered TIPE expression and analyzed its function and influence on DcR3 secretion. Lipopolysaccharide (LPS) was used to stimulate TIPE-overexpressing HCT116 cells, and alterations in signaling pathways were detected. Additionally, inhibitors were used to confirm molecular mechanisms. We found that TIPE and DcR3 were highly expressed in CRC patients and that their expression levels were positively correlated. DcR3 was highly expressed in the plasma of cancer patients. We confirmed that TIPE and DcR3 were highly expressed in HCT116 cells. TIPE overexpression enhanced the transcriptional activity of the DcR3 promoter. TIPE activated the PI3K/AKT signaling pathway to regulate the expression of DcR3, thereby promoting cell proliferation and migration and inhibiting apoptosis. In summary, TIPE and DcR3 are highly expressed in CRC, and both proteins are associated with poor prognosis. TIPE regulates DcR3 expression by activating the PI3K/AKT signaling pathway in CRC, thus promoting cell proliferation and migration and inhibiting apoptosis. These findings may have clinical significance and promise for applications in the treatment or prognostication of CRC.

22 August 2019 in Neurological Sciences
Verified
Journal Article
Closed access
PDF file
FWFeng Wang
Feng Wang
HGHua Ge
Hua Ge
XSXinhui Su
Xinhui Su
RWRu Wang
Ru Wang
JZJianqi Zeng
Jianqi Zeng
JMJiayin Miao
Jiayin Miao

17 September 2021 in Medicine
Verified
Journal Article
Open access
JZJianqi Zeng
Jianqi Zeng
FCFeng Chen
Feng Chen
YCYiqian Chen
Yiqian Chen
MPMuli Peng
Muli Peng
XCXingyu Chen
Xingyu Chen
JMJiayin Miao
Jiayin Miao
For patients with ischemic stroke, intravenous (IV) thrombolysis with Urokinase within 6 hours has been accepted as beneficial, but its application is limited by high risk of hemorrhagic complications after thrombolysis. This study aimed to analyze the risk factors of hemorrhagic complications after intravenous thrombolysis using Urokinase in acute cerebral infarction (ACI) patients. Total 391 consecutive ACI patients were enrolled and divided into 2 groups: the hemorrhagic complications group and the non-hemorrhagic complications group. The related data were collected and analyzed. Univariate analysis showed significant differences in prothrombin time, atrial fibrillation (AF), Mean platelet volume, large platelet ratio (L-PLR), triglyceride (TG), Lactate dehydrogenase, alanine aminotransferase (ALT), high-density lipoprotein, and baseline National Institute of Health Stroke Scale score between the hemorrhagic complications and the non-hemorrhagic complications group (P < .1). Multivariate logistic regression analysis indicated that AF (odds ratio [OR] = 2.91, 95% confidence interval [CI] = 1.06–7.99 P = .039) was the risk factor of hemorrhagic complications, while ALT (OR = 0.27, 95% CI = 0.10–0.72 P = .009) and TG (OR = 0.16, 95% CI = 0.06–0.45 P = .000) were protective factors of hemorrhagic complications. For patients with AF and lower levels of ALT or TG, the risk of hemorrhagic complications might increase after ACI.

23 July 2020 in ACS Omega
Verified
Journal Article
Closed access
EZEnkang Zhang
Enkang Zhang
CYChaozhang Yu
Chaozhang Yu
HTHui Tang
Hui Tang
YLYuntong Li
Yuntong Li
DZDongliang Zuo
Dongliang Zuo
XSXinhui Su
Xinhui Su